Group 1 - The core point of the news is that Haili Biological experienced a stock price increase of 5.08%, reaching 6.41 CNY per share, with a total market capitalization of 4.203 billion CNY as of the report date [1] - Haili Biological, established on July 18, 1981, specializes in the research, production, and sales of animal vaccines, with its main business revenue composition being 71.34% from oral vaccines, 28.61% from IVD, and 0.05% from other sources [1] Group 2 - From the perspective of Haili Biological's top ten circulating shareholders, Guotai Fund's ETF, Guotai Zhongzheng Animal Husbandry ETF (159865), increased its holdings by 3.6987 million shares, totaling 10.2279 million shares, which represents 1.58% of the circulating shares [2] - The Guotai Zhongzheng Animal Husbandry ETF (159865) was established on March 1, 2021, with a current scale of 6.097 billion CNY and has achieved a year-to-date return of 11.41%, ranking 3417 out of 4189 in its category [2]

Group 1: Innovation in Pharmaceuticals - In 2025, China approved a record 76 innovative drugs, significantly surpassing the 48 approved in 2024, marking a historical high [1] - The total amount of foreign licensing transactions for innovative drugs in China exceeded $130 billion in 2025, with over 150 transactions, also a historical high [1] - Among the 76 approved innovative drugs, 47 are chemical drugs, 23 are biological products, and 6 are traditional Chinese medicines, with a high proportion of domestic innovations [1] Group 2: Drug Approval and Clinical Trials - China Medical's subsidiary Tianfang Pharmaceutical received approval for clarithromycin tablets, which passed the consistency evaluation for generic drugs [2] - Microchip Biotech announced that its CS08399 tablets for treating tumors with MTAP deficiency have had their clinical trial application accepted [3] - Frontier Biotech's FB7013 injection, targeting MASP-2 for IgA nephropathy, received acceptance for its clinical trial application, marking it as a first-in-class drug [4] Group 3: Capital Market Activities - Yifang Biotechnology submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as the exclusive sponsor [5] - Wanyi Medical also submitted a listing application to the Hong Kong Stock Exchange, with Guotai Junan International as the exclusive sponsor [6] Group 4: Corporate Investments and Acquisitions - Yunnan Baiyao plans to invest up to 45% of its net assets in financial products in 2026 [7] - Haili Biological's subsidiary intends to acquire 51% stakes in seven dental chain companies for 61.2 million yuan, expecting to increase revenue by approximately 100 million yuan [9] Group 5: Corporate Restructuring and Legal Matters - *ST Chang Pharmaceutical announced that its restructuring investors intend to terminate the restructuring investment agreement [10] - Zai Lab entered a global strategic cooperation and licensing agreement with AbbVie for the development and commercialization of ZG006, with potential milestone payments totaling up to $10.75 billion [11] - Tianyu Biotech's actual controller received a notice from the China Securities Regulatory Commission regarding an investigation into alleged illegal stock reduction [13]

本报告依据中国资产评估准则编制 陕西瑞盛生物科技有限公司拟股权收购事宜 涉及的常州天宁龙洋金铂利口腔门诊部有限公司 股东全部权益 资产评估报告 中和谊评报字[2025]60042 北京中和谊资产评估有限公司 二〇二五年十二月三十一日 | 报告编码: 1111020029202500342 | | | --- | --- | | 合同编号: 20256038 | | | 报告类型: | 非法定评估业务资产评估报告 | | 报告文号: | 中和谊评报字 2025 60042 | | 报告名称: | 陕西瑞盛生物科技有限公司拟股权收购事宜涉及的常州天宁龙洋 金铂利口腔门诊部有限公司股东全部权益 | | 评估结论: 5,800,000.00元 | | | 评估报告日: 2025年12月31日 | | | 评估机构名称: | 北京中和谊资产评估有限公司 | | 王芳芳 签名人员: | (资产评估师) 正式会员 编号:11230101 | | 石俊杰 | (资产评估师) 正式会员 编号:14230068 | | 王芳芳、石俊杰已实名认可 | | | ERREARD | | | 声明 | 1 | | --- | --- | ...

本报告依据中国资产评估准则编制 陕西瑞盛生物科技有限公司拟股权收购事宜 涉及的溧阳金铂利口腔门诊部有限公司 股东全部权益 资产评估报告 中和谊评报字[2025]60043 北京中和谊资产评估有限公司 二〇二五年十二月三十一日 | 声明 | 1 | | --- | --- | | 资产评估报告摘要 | 3 | | 资产评估报告正文 | 6 | | 一、委托人、被评估单位和资产评估委托合同约定的其他资产评估报告使用人概况 6 | | | 二、评估目的 | 12 | | 三、评估对象和评估范围 | 12 | | 四、价值类型 | 13 | | 五、评估基准日 | 14 | | 六、评估依据 | 14 | | 七、评估方法 | 17 | | 八、评估程序实施过程和情况 | 25 | | 九、评估假设 | 26 | | 十、评估结论 | 27 | | 十一、特别事项说明 | 29 | | 十二、资产评估报告使用限制说明 | 29 | | 十三、资产评估报告日 | 32 | | 资产评估报告附件 | 34 | 陕西瑞盛生物科技有限公司拟股权收购事宜涉及的 溧阳金铂利口腔门诊部有限公司股东全部权益·资产评估报告 | 报告编 ...

本报告依据中国资产评估准则编制 陕西瑞盛生物科技有限公司拟股权收购事宜 涉及的常州武进金铂利口腔门诊部有限公司 股东全部权益 资产评估报告 中和谊评报字[2025]60041 北京中和谊资产评估有限公司 二○二五年十二月三十一日 | 报告编码: | 1111020029202500341 | | --- | --- | | 合同编号: | 20256038 | | 报告类型: | 非法定评估业务资产评估报告 | | 报告文号: | 中和谊评报字[2025]60041 | | 报告名称: | 陕西瑞盛生物科技有限公司拟股权收购事宜涉及的常州武进金铂 利口腔门诊部有限公司股东全部权益 | | 评估结论: | 27,700,000.00元 | | 评估报告日 : | 2025年12月31日 | | 评估机构名称: | 北京中和谊资产评估有限公司 | | 签名人员: | 王芳芳 (资产评估师) 正式会员 编号: 11230101 | | | 石俊杰 (资产评估师) 正式会员 编号:14230068 | | | 王芳芳、石俊杰已实名认可 | 声明 一、本资产评估报告依据财政部发布的资产评估基本准则和中国资产评估协会 发 ...

Group 1 - Aerospace Power's main business does not involve commercial aerospace, nor does it have any commercial aerospace-related assets for external investment [1] - Daye Co., Ltd.'s robotic tendon products are still in the exploratory testing phase and have not yet achieved mass production [1] Group 2 - Zhongyan Chemical plans to invest 83.9692 million yuan to expand its production capacity to 10,000 tons of metallic sodium and 15,500 tons of liquid nitrogen annually [1] - Huakang Clean has won the bid for the construction of the laboratory process project (Phase I, first opening area) in Dalian Yinggeshi Science City [1] Group 3 - Lixun Precision intends to repurchase shares worth between 1 billion to 2 billion yuan [1] - Green Island Wind's actual controller's concerted actors plan to reduce their holdings by no more than 1% of shares [1] Group 4 - Guangku Technology expects a year-on-year net profit increase of 152.00% to 172.00% in 2025 [1] - Zhaoli Technology is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure [1]

Group 1: Company Announcements - Zhongwei Company plans to acquire 64.69% equity of Hangzhou Zhonggui through a combination of share issuance and cash payment, aiming to enhance its capabilities in CMP equipment and solutions [1] - Lixun Precision intends to repurchase shares worth between 1 billion to 2 billion RMB for employee stock ownership plans or equity incentives, with a maximum repurchase price of 86.96 RMB per share [2] - ZaiJing Pharmaceutical has reached a global strategic cooperation and licensing agreement with AbbVie for the development and commercialization of ZG006, receiving an upfront payment of 100 million USD [3] - Tianci Materials expects a net profit increase of 127% to 231% for 2025, driven by significant growth in lithium-ion battery material sales [4] - Meike Home plans to acquire 100% equity of Shenzhen Wande Technology through share issuance and cash payment, with stock resuming trading on January 5, 2026 [6][7] - ST KeliDa is planning a change in control, with stock suspension starting January 5, 2026, due to the transfer of 100% equity of its controlling shareholder [8] - Xinzhou Bang intends to invest approximately 260 million USD in a lithium-ion battery materials project in Saudi Arabia, enhancing its global capacity and supply chain [9] Group 2: Financial Performance - Kid's King anticipates a net profit increase of 51.72% to 82.06% for 2025 [9] - Guangku Technology expects a net profit growth of 152% to 172% for 2025 [9] Group 3: Mergers and Acquisitions - Xidi Micro plans to acquire 100% equity of Chengxin Micro for 310 million RMB [9] - Haili Biological's subsidiary intends to acquire 51% equity of seven dental chain companies for 61.2 million RMB [9]

Group 1: Mergers and Acquisitions - Haili Biological's subsidiary, Ruisheng Biological, plans to invest 61.2 million yuan to acquire 51% equity in seven dental chain companies located in Yangzhou and Changzhou, which is expected to increase the company's revenue by approximately 100 million yuan and net profit by over 7 million yuan [1] - Yanggu Huatai has decided to terminate the issuance of shares and cash payment to acquire 99.64% equity in Bomi Technology, opting to negotiate for partial equity acquisition in cash instead [2] - Yachuang Electronics intends to issue shares and pay cash totaling 317 million yuan to purchase 40% equity in Shenzhen Ouchuang Semiconductor and 45% equity in Shenzhen Yihai Nengda, constituting a major asset restructuring [3] Group 2: Earnings Forecasts - Guangku Technology anticipates a net profit attributable to shareholders of 169 million to 182 million yuan for 2025, representing a year-on-year growth of 152% to 172% [4] Group 3: Shareholding Changes - Jianzhijia's actual controller, Yunnan Xiangqun, plans to increase its stake in the company by up to 2% through a concentrated bidding process, with an investment amount of 50 million yuan sourced from its own funds and a loan of up to 45 million yuan from CITIC Bank [5] - Zhenzhong Investment, a significant shareholder of Lvdiaofeng, plans to reduce its stake by no more than 1% through a concentrated bidding process, equating to a maximum of 680,000 shares [6] - Two shareholders of Lingzhi Software plan to reduce their holdings by a combined total of up to 1.43%, with one shareholder reducing by up to 3.281 million shares (0.82% of total shares) and the other by up to 2.4492 million shares (0.61% of total shares) [7] Group 4: Tax Issues - Tianyue Advanced announced that it needs to pay a total of 82.9728 million yuan in corporate income tax and late fees, which will be recorded in the 2025 financial results, expected to reduce the company's net profit for that year [8] - China Pharmaceutical's wholly-owned subsidiary, Hainan Tongyong Sanyang Pharmaceutical and Hainan Kangli Pharmaceutical, received tax notices requiring a total payment of approximately 65.2178 million yuan in taxes and late fees, which will also impact the company's net profit for 2025 [9][10] Group 5: Regulatory Issues - Platelite has received a notice from the China Securities Regulatory Commission regarding a case of suspected illegal information disclosure, leading to an official investigation [11] Group 6: Legal Matters - Baotailong announced that its subsidiary, Shuangyashan Longmei Tiantai Coal Chemical Co., is involved in a significant lawsuit that has entered the second instance, with a ruling requiring it to pay 316 million yuan in contract price and interest, while also receiving compensation and a return of a quality guarantee deposit [12]

Group 1 - The company, Haili Biological, announced that its 18th meeting of the fifth board of directors was held via communication on December 31, 2025 [1] - The meeting reviewed the proposal regarding the acquisition of equity in seven dental chain companies located in Yangzhou and Changzhou [1]

证券代码：603718 证券简称：海利生物 公告编号：2025－064 上海海利生物技术股份有限公司 第五届董事会第十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 上海海利生物技术股份有限公司（以下简称"公司"）第五届董事会第十八次 会议通知于 2025 年 12 月 25 日以电子邮件和电话方式送达全体董事，于 2025 年 12 月 31 日下午以通讯方式召开。本次董事会会议应参加董事 7 人，实际参加董 事 7 名。本次会议符合《公司法》、《公司章程》和《董事会议事规则》的有关规 定，会议的召集、召开合法有效。 二、董事会会议审议情况 具体情况详见同日刊登于上海证券交易所网站（www.sse.com.cn）和公司指 定信息披露报刊《证券时报》、《证券日报》的《上海海利生物技术股份有限公司 经审议，本次董事会以通讯表决方式通过如下议案： 1、 审议通过了《关于控股子公司收购扬州、常州七家口腔连锁公司股权的议 案》 同意控股子公司陕西瑞盛生物科技有限公司（以下简称"瑞盛生物" ...